https://scholars.lib.ntu.edu.tw/handle/123456789/465320
標題: | Dual-triggered drug-release vehicles for synergistic cancer therapy | 作者: | Tu T.-Y Yang S.-J Tsai M.-H Wang C.-H Lee S.-Y Tai-Horng Young MING-JIUM SHIEH |
公開日期: | 2019 | 卷: | 173 | 起(迄)頁: | 788-797 | 來源出版物: | Colloids and Surfaces B: Biointerfaces | 摘要: | Cancer is a complex and tenacious disease. Drug-delivery systems in combination with multimodal therapy strategies are very promising candidates for cancer theranostic applications. In this study, a new drug-delivery vehicle that combine human serum albumin (HSA)- and poly(sodium 4-styrenesulfonate) (PSS)-coated gold nanorod nanoparticles(GNR/PSS/HSA NPs) was developed for synergistic cancer therapy. Doxorubicin (DOX) was loaded onto GNR/PSS/HSA NPs, by electrostatic and hydrophobic forces, to create multimodal DOX@GNR/PSS/HSA NPs. DOX@GNR/PSS/HSA NPs were found to be highly biocompatible and stable in physiological solutions. Furthermore, GNR/PSS/HSA NPs with or without DOX were designed to exhibit strong absorbance in the near-infrared region and high photothermal conversion efficiency. Therefore, bimodal DOX release from DOX@GNR/PSS/HSA NPs could be triggered by an acidic pH and by near-infrared irradiation after NPs preferentially accumulated at tumor sites, leading to a significant chemotherapeutic effect. Moreover, DOX@GNR/PSS/HSA NPs were designed to be applied during chemo- and photo-thermal combination therapy and exhibited a synergistic anticancer effect that was superior to the effect of monotherapy, from both in vitro and in vivo results. These results suggest that DOX@GNR/PSS/HSA NPs are a strong candidate for a nanoplatform for future antitumor therapeutic strategies. ? 2018 |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/465320 | ISSN: | 0927-7765 | DOI: | 10.1016/j.colsurfb.2018.10.043 | SDG/關鍵字: | Biocompatibility; Body fluids; Chemotherapy; Diseases; Drug products; Gold coatings; Gold nanoparticles; Infrared devices; Nanoribbons; Nanorods; Oncology; Targeted drug delivery; Controlled drug release; Gold nanorod; Human serum albumins; Photothermal conversion efficiencies; Photothermal therapy; Physiological solution; Polysodium 4-styrenesulfonate; Triggered drug release; Controlled drug delivery; doxorubicin; gold nanorod; human serum albumin; polystyrenesulfonate sodium; antineoplastic antibiotic; doxorubicin; gold; human serum albumin; nanotube; polymer; styrenesulfonic acid polymer; sulfonic acid derivative; adsorption; animal experiment; animal model; antineoplastic activity; aqueous solution; Article; body weight loss; cancer chemotherapy; cancer inhibition; cell viability; coated particle; concentration response; controlled drug release; controlled study; drug cytotoxicity; drug delivery system; drug solubility; endosome; female; Fourier transform infrared spectroscopy; HeLa cell line; human; human cell; hydrophilicity; hydrophobicity; in vitro study; in vivo study; internalization; lysosome; mouse; nanopharmaceutics; nonhuman; particle size; pH; photothermal therapy; priority journal; static electricity; surface charge; temperature; tumor growth; tumor volume; uterine cervix cancer; zeta potential; animal; chemistry; delayed release formulation; drug formulation; drug release; drug screening; infrared radiation; low level laser therapy; metabolism; molecularly targeted therapy; multimodality cancer therapy; neoplasm; nude mouse; procedures; subcutaneous drug administration; Animals; Antibiotics, Antineoplastic; Combined Modality Therapy; Delayed-Action Preparations; Doxorubicin; Drug Compounding; Drug Liberation; Female; Gold; HeLa Cells; Humans; Hydrogen-Ion Concentration; Infrared Rays; Injections, Subcutaneous; Low-Level Light Therapy; Mice; Mice, Nude; Molecular Targeted Therapy; Nanotubes; Neoplasms; Polymers; Serum Albumin, Human; Sulfonic Acids; Xenograft Model Antitumor Assays |
顯示於: | 醫學工程學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。